Inflammation biomarkers are associated with the incidence of cardiovascular disease: a meta-analysis

Inflammation is a risk factor for cardiovascular disease (CVD), and particular inflammatory parameters can be used to predict the incidence of CVD. The aim of this study was to assess the association between fibrinogen (FIB), interleukin-6 (IL-6), C-reactive protein (CRP) and galectin-3 (Gal-3) and the risk of cardiovascular disease using meta-analysis.PubMed, Embase, Scopus, and Web of Science databases were searched with the appropriate strategies to identify observational studies relevant to this meta-analysis. A random-effects model was used to combine inflammation factor-associated outcomes and cardiovascular disease outcomes, except in the case of galectin-3, where a fixed-effects model was used because of less heterogeneity. Location, age, type of cardiovascular disease, and sample size factors were used to explore heterogeneity in stratification and metaregression for subgroup analysis. A case-by-case literature exclusion approach was used for sensitivity analysis. The funnel plot and Begg's test were combined to assess publication bias.Thirty-three papers out of 11,456 were screened for inclusion in the analysis. Four inflammation biomarkers were significantly associated with the development of CVD: FIB (OR: 1.21, 95% CI: 1.15–1.27, P < 0.001; HR: 1.04, 95% CI: 1.00–1.07, P < 0.05), IL-6 (HR: 1.16, 95% CI: 1.10–1.22, P < 0.001), CRP (OR: 1.25, 95% CI: 1.15–1.35, P < 0.001; HR: 1.20, 95% CI: 1.14–1.25, P < 0.001) and Gal-3 (HR: 1.09, 95% CI: 1.05–1.14, P < 0.001). Location factors help explain the source of heterogeneity, and there is publication bias in the Gal-3 related literature.Taken together, the current research evidence suggests that high levels of fibrinogen, interleukin-6, C-reactive protein and galectin-3 are risk factors for cardiovascular disease and can be used as biomarkers to predict the development of cardiovascular disease to some extent.https://www.crd.york.ac.uk/PROSPERO, identifier: CRD42023391844.

[1]  P. Mathur,et al.  The influence of inflammation on cardiovascular disease in women , 2022, Frontiers in Global Women's Health.

[2]  M. A. Mahmoud,et al.  Galectin-3 is Associated with Heart Failure Incidence: A Meta-Analysis , 2022, medRxiv.

[3]  M. Sadeghi,et al.  High-sensitivity C-reactive protein and low-density lipoprotein cholesterol association with incident of cardiovascular events: Isfahan cohort study , 2022, BMC Cardiovascular Disorders.

[4]  H. Yim,et al.  Cohort study of long working hours and increase in blood high‐sensitivity C‐reactive protein (hsCRP) concentration: Mechanisms of overwork and cardiovascular disease , 2022, Journal of occupational health.

[5]  L. Skov,et al.  Biomarkers of subclinical atherosclerosis in patients with psoriasis , 2021, Scientific Reports.

[6]  M. Trivella,et al.  Biomarkers of Vascular Inflammation for Cardiovascular Risk Prognostication: A Meta-Analysis. , 2021, JACC. Cardiovascular imaging.

[7]  P. Ridker.  From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction? , 2021, Cardiovascular research.

[8]  S. Solomon,et al.  Mid- to late-life inflammation and risk of cardiac dysfunction, HFpEF, and HFrEF in late-life. , 2021, Journal of cardiac failure.

[9]  Yuli Huang,et al.  Non-alcoholic fatty liver disease is associated with increased risk of chronic kidney disease , 2021, Therapeutic advances in chronic disease.

[10]  Y. J. Chai,et al.  Effect of Cigarette Smoking on Thyroid Cancer: Meta-Analysis , 2021, Endocrinology and metabolism.

[11]  P. Ridker,et al.  Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease , 2021, Circulation research.

[12]  S. Myung,et al.  Consumption of artificially sweetened soft drinks and risk of gastrointestinal cancer: a meta-analysis of observational studies , 2021, Public Health Nutrition.

[13]  Sathish Kumar Jayapal,et al.  Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019 , 2020, Journal of the American College of Cardiology.

[14]  A. C. Eddy,et al.  Growth differentiation factor-15 and its role in diabetes and cardiovascular disease. , 2020, Cytokine & growth factor reviews.

[15]  T. Lüscher,et al.  Repurposing Colchicine to Combat Residual Cardiovascular Risk: The LoDoCo2 Trial , 2020, European journal of clinical investigation.

[16]  E. Boerwinkle,et al.  Levels and Change in Galectin‐3 and Association With Cardiovascular Events: The ARIC Study , 2020, Journal of the American Heart Association.

[17]  Yongjun Wang,et al.  The impact of the cumulative burden of LDL-c and hs-CRP on cardiovascular risk: a prospective, population-based study , 2020, Aging.

[18]  O. Melander,et al.  Circulating protein biomarkers predict incident hypertensive heart failure independently of N‐terminal pro‐B‐type natriuretic peptide levels , 2020, ESC heart failure.

[19]  Mingxia Ji,et al.  Dietary inflammatory index and cardiovascular risk and mortality , 2020, Medicine.

[20]  V. Salomaa,et al.  Comparison of Cardiovascular Risk Factors in European Population Cohorts for Predicting Atrial Fibrillation and Heart Failure, Their Subsequent Onset, and Death , 2020, Journal of the American Heart Association.

[21]  Yuli Huang,et al.  Nonalcoholic fatty liver disease is associated with increased risk of atrial fibrillation , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[22]  Liming Yang,et al.  Galectin-3 Is a Potential Mediator for Atherosclerosis , 2020, Journal of immunology research.

[23]  N. Sarrafzadegan,et al.  High Sensitivity C-Reactive Protein Predictive Value for Cardiovascular Disease: A Nested Case Control from Isfahan Cohort Study (ICS) , 2020, Global heart.

[24]  M. Banach,et al.  High‐Sensitivity C‐Reactive Protein Discordance With Atherogenic Lipid Measures and Incidence of Atherosclerotic Cardiovascular Disease in Primary Prevention: The ARIC Study , 2020, Journal of the American Heart Association.

[25]  Liangrong Zheng,et al.  The Biomarkers for Acute Myocardial Infarction and Heart Failure , 2020, BioMed research international.

[26]  D. Levy,et al.  Sex Differences in Circulating Biomarkers of Cardiovascular Disease. , 2019, Journal of the American College of Cardiology.

[27]  V. Fuster,et al.  Negative Risk Markers for Cardiovascular Events in the Elderly. , 2019, Journal of the American College of Cardiology.

[28]  V. Salomaa,et al.  Sex-Specific Epidemiology of Heart Failure Risk and Mortality in Europe: Results From the BiomarCaRE Consortium. , 2019, JACC. Heart failure.

[29]  D. Levy,et al.  Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes. , 2018, Journal of the American College of Cardiology.

[30]  Jennifer G. Robinson,et al.  Comparison of Cardiovascular Risk Factors for Coronary Heart Disease and Stroke Type in Women , 2018, Journal of the American Heart Association.

[31]  Daniel Levy,et al.  Protein Biomarkers of Cardiovascular Disease and Mortality in the Community , 2018, Journal of the American Heart Association.

[32]  Sanjiv J. Shah,et al.  Association of Cardiovascular Biomarkers With Incident Heart Failure With Preserved and Reduced Ejection Fraction , 2018, JAMA cardiology.

[33]  R. Elosua,et al.  Prediction of coronary disease incidence by biomarkers of inflammation, oxidation, and metabolism , 2018, Scientific Reports.

[34]  G. Grosso,et al.  Dietary Inflammatory Index and Cardiovascular Risk and Mortality—A Meta-Analysis , 2018, Nutrients.

[35]  A. Evans,et al.  Ideal Cardiovascular Health and Incident Cardiovascular Disease: Heterogeneity Across Event Subtypes and Mediating Effect of Blood Biomarkers: The PRIME Study , 2017, Journal of the American Heart Association.

[36]  Mohammad Hossein Khosravi,et al.  Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2017, Lancet.

[37]  M. Woodward,et al.  Twenty‐Year Predictors of Peripheral Arterial Disease Compared With Coronary Heart Disease in the Scottish Heart Health Extended Cohort (SHHEC) , 2017, Journal of the American Heart Association.

[38]  P. Libby,et al.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.

[39]  Deepak L. Bhatt,et al.  Single and multiple cardiovascular biomarkers in subjects without a previous cardiovascular event , 2017, European journal of preventive cardiology.

[40]  N. Roberts,et al.  Global cardiovascular risk assessment in the primary prevention of cardiovascular disease in adults: systematic review of systematic reviews , 2017, BMJ Open.

[41]  Hannah R Rothstein,et al.  Basics of meta‐analysis: I2 is not an absolute measure of heterogeneity , 2017, Research synthesis methods.

[42]  N. Limdi,et al.  High-Sensitivity C-Reactive Protein and Risk of Stroke in Atrial Fibrillation (from the Reasons for Geographic and Racial Differences in Stroke Study). , 2016, The American journal of cardiology.

[43]  A. Jaffe,et al.  Biomarker‐based risk prediction in the community , 2016, European journal of heart failure.

[44]  J. Kamińska,et al.  The utility of inflammation and platelet biomarkers in patients with acute coronary syndromes , 2016, Saudi journal of biological sciences.

[45]  Xueli Yang,et al.  Predicting the 10-Year Risks of Atherosclerotic Cardiovascular Disease in Chinese Population: The China-PAR Project (Prediction for ASCVD Risk in China) , 2016, Circulation.

[46]  J. Montaner,et al.  Blood/Brain Biomarkers of Inflammation After Stroke and Their Association With Outcome: From C-Reactive Protein to Damage-Associated Molecular Patterns , 2016, Neurotherapeutics.

[47]  A. Folsom,et al.  Lack of association of plasma gamma prime (γ') fibrinogen with incident cardiovascular disease. , 2016, Thrombosis research.

[48]  Birju S. Patel,et al.  Impact of Race, Ethnicity, and Multimodality Biomarkers on the Incidence of New-Onset Heart Failure With Preserved Ejection Fraction (from the Multi-Ethnic Study of Atherosclerosis). , 2016, The American journal of cardiology.

[49]  Harlan M Krumholz,et al.  Acute Myocardial Infarction in Women: A Scientific Statement From the American Heart Association , 2016, Circulation.

[50]  P. Ridker.  From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection. , 2016, Circulation research.

[51]  P. Whincup,et al.  Prediction of Cardiovascular Disease Risk by Cardiac Biomarkers in 2 United Kingdom Cohort Studies , 2016, Hypertension.

[52]  A. Folsom,et al.  Association of Plasma γ' Fibrinogen With Incident Cardiovascular Disease: The Atherosclerosis Risk in Communities (ARIC) Study. , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[53]  N. Cook,et al.  Usefulness of B-type Natriuretic Peptides to Predict Cardiovascular Events in Women (from the Women's Health Study). , 2015, The American journal of cardiology.

[54]  V. Salomaa,et al.  Predictive value of galectin-3 for incident cardiovascular disease and heart failure in the population-based FINRISK 1997 cohort. , 2015, International journal of cardiology.

[55]  S. Oparil,et al.  Estrogen and Cardiovascular Disease: Is Timing Everything? , 2015, The American journal of the medical sciences.

[56]  J. Jeppesen,et al.  Adipocytokines, C-Reactive Protein, and Cardiovascular Disease: A Population-Based Prospective Study , 2015, PloS one.

[57]  P.-Y. Zhang,et al.  Biomarkers and heart disease. , 2014, European review for medical and pharmacological sciences.

[58]  E. Barrett-Connor,et al.  Galectin-3 is independently associated with cardiovascular mortality in community-dwelling older adults without known cardiovascular disease: The Rancho Bernardo Study. , 2014, American heart journal.

[59]  D. Levy,et al.  Galectin 3 and incident atrial fibrillation in the community. , 2014, American heart journal.

[60]  D. Levy,et al.  Protein Biomarkers of New-Onset Cardiovascular Disease: Prospective Study From the Systems Approach to Biomarker Research in Cardiovascular Disease Initiative , 2014, Arteriosclerosis, thrombosis, and vascular biology.

[61]  Daniel F. Freitag,et al.  Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. , 2014, European heart journal.

[62]  R. Dreyer,et al.  Evaluation of gender differences in Door-to-Balloon time in ST-elevation myocardial infarction. , 2013, Heart, lung & circulation.

[63]  A. Catapano,et al.  Soluble Lectin-Like Oxidized Low Density Lipoprotein Receptor-1 as a Biochemical Marker for Atherosclerosis-Related Diseases , 2013, Disease markers.

[64]  J. Murabito,et al.  Multiple Inflammatory Biomarkers in Relation to Cardiovascular Events and Mortality in the Community , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[65]  L. Afonso,et al.  Association of novel biomarkers with future cardiovascular events is influenced by ethnicity: results from a multi-ethnic cohort. , 2013, International journal of cardiology.

[66]  K. Yamagishi,et al.  C-reactive protein levels and risk of stroke and its subtype in Japanese: The Circulatory Risk in Communities Study (CIRCS). , 2011, Atherosclerosis.

[67]  Olle Melander,et al.  Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation. , 2010, Journal of the American College of Cardiology.

[68]  D. Levy,et al.  Relation of multiple inflammatory biomarkers to incident atrial fibrillation. , 2009, The American journal of cardiology.

[69]  J. Schwartz,et al.  Relation of inflammation to depression and incident coronary heart disease (from the Canadian Nova Scotia Health Survey [NSHS95] Prospective Population Study). , 2009, The American journal of cardiology.

[70]  P. Ridker.  C-reactive protein: eighty years from discovery to emergence as a major risk marker for cardiovascular disease. , 2009, Clinical chemistry.

[71]  B. Hedblad,et al.  Inflammation-sensitive plasma proteins are associated with increased incidence of heart failure: a population-based cohort study. , 2009, Atherosclerosis.

[72]  Saskia le Cessie,et al.  Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study , 2009, BMJ : British Medical Journal.

[73]  Gerta Rücker,et al.  Bmc Medical Research Methodology Open Access Undue Reliance on I 2 in Assessing Heterogeneity May Mislead , 2022 .

[74]  T. Hansen,et al.  C-reactive protein, insulin resistance and risk of cardiovascular disease: a population-based study , 2008, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[75]  Alberto Smith,et al.  Galectin-3 Is an Amplifier of Inflammation in Atherosclerotic Plaque Progression Through Macrophage Activation And Monocyte Chemoattraction , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[76]  R. Sacco,et al.  High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. , 2006, Archives of internal medicine.

[77]  K. Yamagishi,et al.  Plasma Fibrinogen Concentrations and Risk of Stroke and Its Subtypes Among Japanese Men and Women , 2006, Stroke.

[78]  C. Molina,et al.  Poststroke C-Reactive Protein Is a Powerful Prognostic Tool Among Candidates for Thrombolysis , 2006, Stroke.

[79]  Carl J Pepine,et al.  Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. , 2006, Journal of the American College of Cardiology.

[80]  R. Westendorp,et al.  In a population-based prospective study, no association between high blood pressure and mortality after age 85 years , 2006, Journal of hypertension.

[81]  B. Hedblad,et al.  Occupation, Marital Status, and Low-Grade Inflammation: Mutual Confounding or Independent Cardiovascular Risk Factors? , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[82]  E. Boerwinkle,et al.  Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. , 2005, Archives of internal medicine.

[83]  H Tunstall-Pedoe,et al.  Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. , 2005, JAMA.

[84]  S. Kritchevsky,et al.  Inflammatory markers and cardiovascular health in older adults. , 2005, Cardiovascular research.

[85]  A. Folsom,et al.  Risk factors for cardiovascular event recurrence in the Atherosclerosis Risk in Communities (ARIC) study. , 2005, American heart journal.

[86]  S. Rubin,et al.  Inflammatory Markers and Onset of Cardiovascular Events: Results From the Health ABC Study , 2003, Circulation.

[87]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[88]  N. Rothwell,et al.  An early and sustained peripheral inflammatory response in acute ischaemic stroke: relationships with infection and atherosclerosis , 2003, Journal of Neuroimmunology.

[89]  D. Levy,et al.  Inflammatory Markers and Risk of Heart Failure in Elderly Subjects Without Prior Myocardial Infarction: The Framingham Heart Study , 2003, Circulation.

[90]  W. Kannel.  Coronary heart disease risk factors in the elderly. , 2002, The American journal of geriatric cardiology.

[91]  R. D'Agostino,et al.  Association of Fibrinogen With Cardiovascular Risk Factors and Cardiovascular Disease in the Framingham Offspring Population , 2000, Circulation.

[92]  P. Ridker,et al.  Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. , 2000, Circulation.

[93]  P. Ridker,et al.  C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. , 2000, The New England journal of medicine.

[94]  A. Folsom,et al.  Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. , 1999, Circulation.

[95]  P. Ridker,et al.  A prospective study of fibrinogen and risk of myocardial infarction in the Physicians' Health Study. , 1999, Journal of the American College of Cardiology.

[96]  A. Döring,et al.  C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. , 1999, Circulation.

[97]  A. Evans,et al.  Associations of Fibrinogen, Factor VII and PAI-1 with Baseline Findings among 10,500 Male Participants in a Prospective Study of Myocardial Infarction , 1998, Thrombosis and Haemostasis.

[98]  A. Rumley,et al.  Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[99]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[100]  C. Begg,et al.  Operating characteristics of a rank correlation test for publication bias. , 1994, Biometrics.

[101]  R. D'Agostino,et al.  Fibrinogen and risk of cardiovascular disease. The Framingham Study. , 1987, JAMA.

[102]  OUP accepted manuscript , 2022, European Heart Journal.

[103]  A. Evans,et al.  Plasma fibrinogen explains much of the difference in risk of coronary heart disease between France and Northern Ireland. The PRIME study. , 2003, Atherosclerosis.